Considering even emmetropic eyes elongate, what are the limits of myopia control efficacy? This novel analysis explores the absolute axial elongation of treated and untreated myopes in the MiSight 3-year clinical trial in comparison to previously published models of myopic and emmetropic eye growth. The results indicate a potential limit to the short-term percentage efficacy of myopia control treatments.
This study reports two year results from a randomized clinical trial examining Defocus Incorporated Multiple Segments (DIMS) spectacle lenses for myopia control. The findings showed around 50% refractive and 60% axial length efficacy in Hong Kong Chinese children, with an absolute effect of 0.44D lower refraction and 0.34mm less axial elongation in DIMS wearers.
This study reports one year results from an ongoing randomized clinical trial examining spectacle lenses with highly aspherical lenslet (HAL) or slightly aspherical lenslet (SAL) technology. The findings showed the HAL lens controlled refractive and axial progression by 60-70% and SAL by 30-40% over the first 12 months.
This study evaluates how orthok treatment zone diameter influences change in refraction and axial eye length over 1-year in children previously fit with orthok lenses of varying back optic zone diameter, to reveal that where treatment zone diameter was less than pupil diameter orthok’s myopia control efficacy appeared to be improved.
The purpose of this 2 year study was to determine the effect of MiSight contact lenses used to control myopia on binocular vision and accommodation in children, as compared with children wearing SV spectacles, with the researches finding no significant differences in binocular and accommodative measures between the study groups.
Despite being used for myopia management for many years, significant controversy exists in both literature and clinical optometric practice regarding the optimal concentration of atropine. The LAMP study sheds light on this mystery by investigating efficacy of 0.05%, 0.025% and 0.01% atropine for slowing myopia progression.
This 2019 study evaluated 3-year MiSight efficacy in a randomised clinical trial conducted across four different sites, in Singapore, Canada, Portugal and the UK to yield promising findings, with efficacy results comparable to previous studies, and overall high satisfaction reported by subjects. Eye Care Practitioners can utilise these results to confidently educate patients and their families on the efficacy of this treatment option.
The authors conducted a 2-year double blinded, randomised control trial to evaluate the efficacy of novel contact lens designs for myopia control. Lens I and II induced myopic defocus across a large portion of the retina, while Lens III and IV featured an extended depth of focus incorporating higher order aberrations to modulate retinal image quality. This technology is utilised in the Mark’Ennovy Mylo the and Seed 1-Day Pure EDOF lens.